Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease - PubMed (original) (raw)
. 1991 Sep 1;78(5):1373-80.
Affiliations
- PMID: 1652311
Free article
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease
P Reusser et al. Blood. 1991.
Free article
Abstract
The high rate of severe cytomegalovirus (CMV) disease after bone marrow transplantation (BMT) is related to the profound immunodeficiency posttransplant. Because cytotoxic T lymphocytes (CTL) have been implicated in resistance to viral infections, we examined the restoration of the CMV-specific CTL response in 20 patients who received bone marrow from HLA-matched, CMV-seropositive donors. Blood specimens were obtained from patients at 1, 2, and 3 months after BMT and from the donors on a single occasion. Peripheral blood mononuclear cells were cocultured with CMV-infected donor-derived fibroblasts for 2 weeks and then tested for cytotoxicity against CMV-infected and uninfected autologous or HLA-mismatched fibroblasts. Cytolytic activity was detected in all 20 donors, with specificity for autologous CMV-infected targets demonstrable in 17 (median CMV-specific lysis at an effector:target ratio of 15:1 was 32%, range 18% to 83%). Specific lysis was mediated by CD8+, class I-restricted T cells, as shown by inhibition with anti-class I monoclonal antibody and by selective depletion of effector cells. By contrast, CMV-specific CTL were detected in only 10 of 20 patients after BMT (median lysis 29% at 3 months post-BMT). None of these 10 patients developed CMV pneumonia, whereas 6 of the 10 patients with an undetectable CMV-specific CTL response after BMT died with CMV pneumonia. These results demonstrate that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease. Approaches to reconstitute CMV immunity in BMT patients by adoptive transfer of CMV-specific CD8+ CTL clones derived from the bone marrow donor are now being pursued.
Similar articles
- Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants.
Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Reusser P, et al. Blood. 1997 May 15;89(10):3873-9. Blood. 1997. PMID: 9160696 - HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells.
Lindsley MD, Torpey DJ 3rd, Rinaldo CR Jr. Lindsley MD, et al. J Immunol. 1986 Apr 15;136(8):3045-51. J Immunol. 1986. PMID: 2420881 - Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Walter EA, et al. N Engl J Med. 1995 Oct 19;333(16):1038-44. doi: 10.1056/NEJM199510193331603. N Engl J Med. 1995. PMID: 7675046 Clinical Trial. - Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
Riddell SR, Reusser P, Greenberg PD. Riddell SR, et al. Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S966-73. doi: 10.1093/clind/13.supplement_11.s966. Rev Infect Dis. 1991. PMID: 1664137 Review. - Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited.
Barry SM, Johnson MA, Janossy G. Barry SM, et al. Bone Marrow Transplant. 2000 Sep;26(6):591-7. doi: 10.1038/sj.bmt.1702562. Bone Marrow Transplant. 2000. PMID: 11035367 Free PMC article. Review.
Cited by
- Different Antigen-Specific CD4+ and CD8+ T-Cell Response against HCMV Proteins in Pregnant Women with Primary Infection and in Control Subjects with Remote Infection.
Zavaglio F, d'Angelo P, Fornara C, Zelini P, Comolli G, Furione M, Arossa A, Spinillo A, Lilleri D, Baldanti F. Zavaglio F, et al. J Clin Med. 2024 Sep 13;13(18):5448. doi: 10.3390/jcm13185448. J Clin Med. 2024. PMID: 39336935 Free PMC article. - CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation.
Zamora D, Xie H, Sadowska-Klasa A, Kampouri E, Biernacki MA, Ueda Oshima M, Duke E, Green ML, Kimball LE, Holmberg L, Waghmare A, Greninger AL, Jerome KR, Hill GR, Hill JA, Leisenring WM, Boeckh MJ. Zamora D, et al. Blood Adv. 2024 Sep 10;8(17):4568-4580. doi: 10.1182/bloodadvances.2023012234. Blood Adv. 2024. PMID: 38924728 Free PMC article. - Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.
Al-Talib M, Dimonte S, Humphreys IR. Al-Talib M, et al. Cell Mol Immunol. 2024 Sep;21(9):982-998. doi: 10.1038/s41423-024-01140-2. Epub 2024 Mar 8. Cell Mol Immunol. 2024. PMID: 38459243 Free PMC article. Review. - Modulation of cytomegalovirus immune evasion identifies direct antigen presentation as the predominant mode of CD8 T-cell priming during immune reconstitution after hematopoietic cell transplantation.
Holtappels R, Büttner JK, Freitag K, Reddehase MJ, Lemmermann NA. Holtappels R, et al. Front Immunol. 2024 Feb 15;15:1355153. doi: 10.3389/fimmu.2024.1355153. eCollection 2024. Front Immunol. 2024. PMID: 38426094 Free PMC article. - Persistent Low-Level Variants in a Subset of Viral Genes Are Highly Predictive of Poor Outcome in Immunocompromised Patients With Cytomegalovirus Infection.
Venturini C, Colston JM, Charles O, Lankina A, Best T, Atkinson C, Forrest C, Williams CA, Rao K, Worth A, Thorburn D, Harber M, Griffiths P, Breuer J. Venturini C, et al. J Infect Dis. 2024 Aug 16;230(2):e427-e436. doi: 10.1093/infdis/jiae001. J Infect Dis. 2024. PMID: 38181168 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials